Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of subretinal NGGT007 for neovascular age-related macular degeneration
CTR20250167Phase 2Active
- Sponsor
- Nuojiebei Biotech
- Start
- Jan 2025
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NGGT007 in exudative macular degeneration, sponsored by Nuojiebei Biotech. Primary endpoints: Number, severity, and incidence of ocular and systemic adverse events and serious adverse events and Change from baseline in best-corrected visual acuity measured by ETDRS letter score in the study eye. Started Jan 2025; status: active.
02
Drugs
NGGT007
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20250167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250167.